CVRx (CVRX) Stock Price
CVRx Price
Revenue has compounded at 49.6% per year over the past 6 years to 50.82 M USD. CVRx's net margin stands at -104.9%, up from -398.2% several years earlier. Analysts set a median price target of 12.24 USD, implying 317.7% above the current price. Of 13 analysts, 11 rate the stock a buy — an overall Buy consensus. Over the past year CVRx shares have lost 7.6%. The stock trades about 54% above its 52-week low.
CVRx stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of CVRx over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how CVRx stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing CVRx's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | CVRx Price |
|---|---|
| 9/8/2026 | 2.93 USD |
| 9/4/2026 | 3.05 USD |
| 9/3/2026 | 3.01 USD |
| 9/2/2026 | 3.07 USD |
| 9/1/2026 | 3.04 USD |
| 8/31/2026 | 2.96 USD |
| 8/30/2026 | 2.90 USD |
| 8/28/2026 | 3.03 USD |
| 8/27/2026 | 3.15 USD |
| 8/26/2026 | 3.27 USD |
| 8/25/2026 | 3.37 USD |
| 8/24/2026 | 3.07 USD |
| 8/21/2026 | 2.84 USD |
| 8/20/2026 | 2.84 USD |
| 8/19/2026 | 2.79 USD |
| 8/18/2026 | 2.82 USD |
| 8/17/2026 | 2.75 USD |
| 8/14/2026 | 3.08 USD |
| 8/13/2026 | 2.94 USD |
| 8/12/2026 | 2.58 USD |
| 8/10/2026 | 2.37 USD |
| 8/7/2026 | 2.39 USD |
| 8/6/2026 | 2.39 USD |
| 8/5/2026 | 2.20 USD |
| 8/4/2026 | 2.22 USD |
| 8/3/2026 | 2.21 USD |
| 7/31/2026 | 2.08 USD |
| 7/30/2026 | 2.16 USD |
| 7/29/2026 | 2.01 USD |
| 7/27/2026 | 1.98 USD |
CVRx Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
CVRx Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.00 | 6.00 | 13.00 | 22.00 | 39.00 | 51.00 | 56.00 | 58.00 | 66.00 | 76.00 | 111.00 | 123.00 |
| – | – | 116.67 | 69.23 | 77.27 | 30.77 | 9.80 | 3.57 | 13.79 | 15.15 | 46.05 | 10.81 |
| 66.67 | 66.67 | 69.23 | 77.27 | 84.62 | 82.35 | 85.71 | 85.71 | 85.71 | 85.71 | 85.71 | 85.71 |
| 4.00 | 4.00 | 9.00 | 17.00 | 33.00 | 42.00 | 48.00 | 49.71 | 56.57 | 65.14 | 95.14 | 105.43 |
| -12.00 | -11.00 | -40.00 | -42.00 | -43.00 | -55.00 | -47.00 | -49.00 | -47.00 | -44.00 | -29.00 | -25.00 |
| -200.00 | -183.33 | -307.69 | -190.91 | -110.26 | -107.84 | -83.93 | -84.48 | -71.21 | -57.89 | -26.13 | -20.33 |
| -14.00 | -14.00 | -43.00 | -41.00 | -41.00 | -59.00 | -53.00 | -52.00 | -49.00 | -45.00 | -33.00 | -29.00 |
| – | – | 207.14 | -4.65 | – | 43.90 | -10.17 | -1.89 | -5.77 | -8.16 | -26.67 | -12.12 |
| 26.22 | 0.36 | 20.37 | 20.59 | 20.83 | 22.60 | 26.22 | 26.22 | 26.22 | 26.22 | 26.22 | 26.22 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales CVRx generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue CVRx retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare CVRx's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares CVRx has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against CVRx's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
CVRx stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
CVRx Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
CVRx business model & stock analysis
CVRx SWOT Analysis
Strengths
CVRx Inc boasts several notable strengths that contribute to its success in the market. These strengths include:
- A strong and experienced management team
- Pioneering medical technology solutions
- Patented and proprietary products offering a competitive edge
- Established partnerships with leading healthcare providers
- Strong brand reputation and recognition
While CVRx Inc has several strengths, there are also certain weaknesses that should be considered. These weaknesses include:
- Reliance on a limited product portfolio
- Dependence on a specific market segment
- Limited geographical presence
- High research and development costs
- Competitive pressure from larger medical device companies
CVRx Inc can capitalize on various opportunities in the market to further expand its business. These opportunities include:
- Increasing demand for innovative healthcare solutions
- Growing global healthcare market
- Rising prevalence of cardiovascular diseases
- Expansion into new geographical regions
- Potential acquisitions or partnerships for diversification
Despite its strengths, CVRx Inc faces certain threats that could impact its performance and market position. These threats include:
- Stringent regulatory requirements for medical device approvals
- Increasing competition from both established and emerging companies
- Economic downturn affecting healthcare spending
- Technological advancements by competitors
- Changes in reimbursement policies
Weaknesses
While CVRx Inc has several strengths, there are also certain weaknesses that should be considered. These weaknesses include:
- Reliance on a limited product portfolio
- Dependence on a specific market segment
- Limited geographical presence
- High research and development costs
- Competitive pressure from larger medical device companies
CVRx Inc can capitalize on various opportunities in the market to further expand its business. These opportunities include:
- Increasing demand for innovative healthcare solutions
- Growing global healthcare market
- Rising prevalence of cardiovascular diseases
- Expansion into new geographical regions
- Potential acquisitions or partnerships for diversification
Despite its strengths, CVRx Inc faces certain threats that could impact its performance and market position. These threats include:
- Stringent regulatory requirements for medical device approvals
- Increasing competition from both established and emerging companies
- Economic downturn affecting healthcare spending
- Technological advancements by competitors
- Changes in reimbursement policies
Opportunities
CVRx Inc can capitalize on various opportunities in the market to further expand its business. These opportunities include:
- Increasing demand for innovative healthcare solutions
- Growing global healthcare market
- Rising prevalence of cardiovascular diseases
- Expansion into new geographical regions
- Potential acquisitions or partnerships for diversification
Despite its strengths, CVRx Inc faces certain threats that could impact its performance and market position. These threats include:
- Stringent regulatory requirements for medical device approvals
- Increasing competition from both established and emerging companies
- Economic downturn affecting healthcare spending
- Technological advancements by competitors
- Changes in reimbursement policies
Threats
Despite its strengths, CVRx Inc faces certain threats that could impact its performance and market position. These threats include:
- Stringent regulatory requirements for medical device approvals
- Increasing competition from both established and emerging companies
- Economic downturn affecting healthcare spending
- Technological advancements by competitors
- Changes in reimbursement policies
CVRx Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
CVRx Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
CVRx historical P/E ratio, EBIT multiple, and P/S ratio
CVRx annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
CVRx shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current CVRx forecasts and price targets in September 2026
Analyst Price Targets 2026CVRx Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/17/2026 | Maintained | Overweight | 41 | |
| 8/7/2026 | Downgrade | BuyHold | – | |
| 4/14/2026 | Maintained | Buy | 64 | |
| 2/13/2026 | Maintained | Buy | 64 | |
| 11/6/2025 | Maintained | Overweight | 41 | |
| 11/6/2025 | Maintained | Buy | 64 | |
| 8/5/2025 | Maintained | Overweight | 41 | |
| 5/9/2025 | Maintained | Overweight | 50 | |
| 5/9/2025 | Downgrade | NeutralUnderweight | 59 | |
| 4/8/2025 | Maintained | Buy | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
CVRx Earnings Calls
CVRx Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/6/2026 | -0.53USD | - | 15.86 MUSD | - | 2026 Q2 |
| 5/11/2026 | -0.51USD | - | 14.77 MUSD | - | 2026 Q1 |
| 2/12/2026 | -0.45USD | - | 16.08 MUSD | - | 2025 Q4 |
| 7/28/2022 | -0.54USD | - | 4.77 MUSD | - | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the CVRx stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
CVRx shareholder structure
| % | Name |
|---|---|
15.35620% | |
7.45685% | |
4.75185% | |
4.70512% | |
3.84427% | |
3.47415% |
CVRx Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
19.60% | SEC ↗ | |
17.20% | SEC ↗ | |
15.40% | SEC ↗ | |
9.00% | SEC ↗ | |
9.00% | SEC ↗ | |
9.00% | SEC ↗ | |
7.80% | SEC ↗ | |
7.80% | SEC ↗ | |
7.80% | SEC ↗ | |
7.80% | SEC ↗ |
CVRx Executives and Management Board
12 members · avg. age 58 · 8 % women
Mr. Kevin Hykes (59)
President, Chief Executive Officer, Director · since 2022
8.76 M USD
Management
Mr. Jared Oasheim (42)
Chief Financial Officer
Mr. Robert John (52)
Chief Revenue Officer
Mr. Paul Verrastro (62)
Chief Marketing and Strategy Officer
Mr. Brent Binkowski (56)
Chief Operating Officer
Dr. Philip Adamson (65)
Chief Medical Officer
Board of Directors
Mr. Mitchell Hill (66)
Independent Director
Mr. Kevin Ballinger (52)
Independent Director
Mr. Joseph Slattery (60)
Lead Independent Director
Dr. Mudit Jain (56)
Independent Director
Mr. Kirk Nielsen (51)
Independent Director
Ms. Martha Shadan (69)
Independent Director
Frequently asked questions about CVRx
The primary business model of CVRx Inc is focused on developing and commercializing innovative medical technologies for the treatment of cardiovascular diseases. CVRx's flagship product, the BAROSTIM NEO®, is a specialized implantable device that utilizes neuromodulation therapy to treat patients with heart failure, resistant hypertension, and chronic kidney disease. This revolutionary technology works by electrically activating the baroreflex, a natural mechanism in the body that regulates cardiovascular function. With its advanced medical devices, CVRx aims to provide effective and alternate solutions to improve patients' quality of life and overall cardiac health.
CVRx Inc is primarily active in the medical device industry.
The main competitors of CVRx Inc in the market include companies like Medtronic, Boston Scientific, and Abbott Laboratories. These companies operate in the medical device industry and offer products and solutions similar to CVRx Inc. Medtronic, a global leader in medical technology, develops innovative therapies for various health conditions including heart failure, where CVRx Inc primarily focuses. Boston Scientific is another significant competitor known for its medical devices and solutions, including those related to heart failure. Abbott Laboratories also competes in this space, providing advanced medical technologies and treatments. These competitors pose challenges to CVRx Inc in terms of product offering, market share, and innovation.
CVRx Inc is a medical technology company established in 2001, specializing in the development of innovative therapies for patients with chronic heart and autonomic nervous system disorders. The company's headquarters are located in Minneapolis, Minnesota, USA. CVRx Inc is renowned for its breakthrough Barostim Neo system, an implantable device that delivers Baroreflex Activation Therapy® (BAT) to help manage treatment-resistant hypertension (high blood pressure). This therapy has received approval in Europe and other international markets, allowing CVRx Inc to provide a unique solution to patients suffering from this condition. CVRx Inc has a rich history of pioneering advancements in medical technology for cardiovascular health.
CVRx Inc has achieved several significant milestones in its corporate journey. The company successfully received FDA approval for its innovative Barostim Neo System in 2019, marking a major breakthrough in the treatment of heart failure. CVRx Inc also completed a pivotal clinical trial, demonstrating substantial improvement in patients' quality of life and reduction in heart failure-related hospitalizations. In addition, CVRx Inc secured significant funding through successful financing rounds, enabling further research and development efforts. These milestones highlight the company's commitment to revolutionizing cardiovascular healthcare and position CVRx Inc as a leading player in the field.
CVRx Inc is primarily present in the United States.
CVRx Inc represents a strong commitment to improving patient outcomes and transforming the treatment of cardiovascular diseases. The company believes in innovation and aims to provide groundbreaking medical technologies. CVRx focuses on developing and commercializing the BAROSTIM NEO, a neuromodulation therapy that helps regulate the body's natural cardiovascular function. With its dedication to scientific research and cutting-edge solutions, CVRx Inc is dedicated to making a positive impact in the lives of patients suffering from conditions like heart failure and hypertension.
Analysts currently set an average price target of 11.73 USD for the CVRx stock (median: 12.24 USD), implying +314.5 % versus the latest price. The consensus is based on 13 analyst ratings.
13 analysts currently rate the CVRx stock: 11 recommend buying, 1 holding and 1 selling. For 2026, analysts expect CVRx to generate revenue of 58.85 M USD and earnings per share of -2.02 USD.
Converted at the current exchange rate, the CVRx share trades at 2.52 EUR (2.93 USD).
The CVRx share (CVRX) is listed on 1 stock exchanges, including: NASDAQ (CVRX).
CVRx Inc. is a biomedical company that develops innovative therapies for the treatment of cardiovascular diseases. The company was founded in Minneapolis in 2001 with the goal of helping patients by developing solutions that can improve quality of life and prolong life. CVRx's core business is the development of implantable medical devices that work with the patented Baroreflex Activation Therapy. The technology regulates blood pressure by stimulating the baroreflex, a vital mechanism that regulates blood pressure to a healthy level. This therapy regulates the body's cardiovascular system, leading to improved physical function and reduced medical complications. CVRx's flagship product is the Barostim Neo™ Baroreflex Activation Therapy (BAT), which is used to treat patients with severe heart failure and hypertension. The system consists of an implantable stimulator and an external programmer used by doctors to customize the therapy to each patient's specific needs. Barostim Neo™ was approved by the US Food and Drug Administration (FDA) in 2019 and has been approved in Europe since 2009. In addition to Barostim Neo™, CVRx is also working on the development of other devices and technologies for the treatment of cardiovascular diseases. This includes systems for regular monitoring of vital signs and diagnostic devices for the early detection of heart failure. CVRx is a global company with offices in North America and Europe. The company has over 150 employees, including experts in research and development, clinical trials, production, and distribution. CVRx collaborates closely with medical professionals, insurance providers, and patient organizations to ensure broad acceptance and availability of its products. The company's business operations are based on an innovative and cost-conscious approach. CVRx aims to increase access to innovative therapies while also reducing healthcare costs. Barostim Neo™ is an example of this approach and has the potential to reduce healthcare costs by decreasing medical complications and hospitalizations. In summary, CVRx is an innovative and growing company focused on the development of therapies for the treatment of cardiovascular diseases. The Barostim Neo™ is the company's flagship product and has already played a significant role in treating patients with severe heart failure and hypertension. CVRx continues to work on developing new solutions that can improve quality of life and prolong life for patients.
The expected revenue of CVRx is 58.85 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of CVRx is -52.87 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of CVRx is currently -1.45. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the CVRx stock.
The price-to-sales ratio (P/S) of CVRx is currently 1.31. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the CVRx stock.
The Eulerpool Quality Score for CVRx is 3/10.
The ISIN of CVRx is US1266381052. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of CVRx is CVRX. The ticker symbol is used to trade CVRx shares on the stock exchange.
CVRx paid dividends every year for the past 0 years.
CVRx is assigned to the 'Health' sector.
The dividends of CVRx are distributed in USD.
CVRx stock
CVRx Peer Group
CVRx Ticker
CVRx FIGI
All fundamentals and in-depth analysis of CVRx
Our stock analysis for CVRx stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CVRx. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.